 - Patients with unresectable cancer for which there are genomic drivers with corresponding Food and Drug Administration FDA approved or experimental drugs available, e.g. non-small cell lung cancer; andor patients with histologically confirmed metastatic malignancy that have failed standard treatment or cannot tolerate standard treatment as deemed by the treating physician 